The question of Novel Food approval is the single biggest issue facing the CBD edibles market, and perhaps the entire CBD market, in Europe. Hopes that there might be an easy way around the regulatory requirement seem unrealistic, and understanding exactly what the Novel Food process entails must therefore now be a top priority for any player hoping to market mainstream CBD products in Europe.
This report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway. Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call related to Novel Food with CBD-Intel’s analyst team.
CBD-Intel does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CBD-Intel, does not accept any liability or responsibility for information or views published.